白雲電器(603861.SH):投資參股的品高股份將於12月30日在科創板掛牌上市
格隆匯12月29日丨白雲電器(603861.SH)公佈,公司投資參股的廣州市品高軟件股份有限公司(“品高股份”)於2021年12月29日發佈了《首次公開發行股票科創板上市公吿書》,其股票將於2021年12月30日在上海證券交易所科創板正式掛牌上市,股票簡稱:品高股份,股票代碼:688227,發行價格:37.09元/股。
截至公吿披露日,公司持有品高股份224.4315萬股,佔其首次公開發行前總股本的2.65%,佔其首次公開發行後總股本的1.99%。公司持有的品高股份上述股份自其上市之日起12個月內不得轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.